Financial Gravity Asset Management, Inc. Alkermes Plc. Transaction History

Financial Gravity Asset Management, Inc.

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	BUY	$26.4 - $32.56 $26 - $32	1 New	1 $39,000
Q4 2022 Feb 15, 2023	BUY	$21.94 - $26.24 $570 - $682	26 New	26 $11,000
Q1 2021 May 17, 2021	SELL	$18.21 - $23.2 $0 - $0	0 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$15.39 - $22.1 $0 - $0	0 New	0 $0
Q2 2020 Aug 13, 2020	SELL	$13.31 - $19.41 $26 - $38	-2 Closed	0 $0
Q1 2020 May 12, 2020	SELL	$13.06 - $21.24 $65 - $106	-5 Reduced 71.43%	2 $0
Q4 2019 Feb 28, 2020	SELL	$17.29 - $21.74 $17 - $21	-1 Reduced 12.5%	7 $20,000
Q3 2019 Oct 15, 2019	BUY	$19.51 - $24.28 $39 - $48	2 Added 33.33%	8 $0
Q2 2019 Jul 26, 2019	SELL	$21.47 - $37.33 $236 - $410	-11 Reduced 64.71%	6 $0
Q1 2019 Apr 19, 2019	BUY	$28.4 - $36.49 $340 - $437	12 Added 240.0%	17 $1,000
Q2 2018 Aug 14, 2018	SELL	$40.56 - $51.36 $40 - $51	-1 Reduced 16.67%	5 $0
Q1 2018 May 23, 2018	BUY	$53.61 - $67.26 $321 - $403	6 New	6 $0

361

181M

175K

96.6K

Ticker ALKS
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 164,254,000
Market Cap $4.73B
Description
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ...

Get notified when there are updates to the investment portfolio of Financial Gravity Asset Management, Inc., based on Form 13F filings with the SEC.

Stay updated on Financial Gravity Asset Management, Inc. with notifications on news.